OPTHEA LIMITED (OPT)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
OPT - OPTHEA LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index: ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Opthea is an Australian healthcare company specialising in the development and commercialisation of therapies to combat eye diseases. Founded in 1984, the company listed on the ASX in 1991.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.65
14 May |
-0.025 OPEN $0.69 |
-3.70% HIGH $0.69 |
942,557 LOW $0.65 |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -45.1 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | -1.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -179.3 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -131,469.74 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -694.96 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -693.52 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -179.93 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -694.96 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -729.64 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -179.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 134 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | - |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 20.25 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | - |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 223 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 182 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
OPT STOCK CHART
FNArena News on OPT
1 |
Rudi’s View: February 2024 Is A Blue Sky AffairFeb 14 2024 - Rudi's View |
2 |
Australian Broker Call *Extra* Edition – Oct 18, 2023Oct 18 2023 - Daily Market Reports |
3 |
Australian Broker Call *Extra* Edition – Aug 30, 2023Aug 30 2023 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Jul 27, 2023Jul 27 2023 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Sep 13, 2022Sep 13 2022 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
2 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
3 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
4 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
5 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
6 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |